Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-octreotide in patients with advanced neuroendocrine tumors.

被引：0
|
作者：
Schipper, ML [1 ]
Gotthardt, M [1 ]
Behe, M [1 ]
Arnold, R [1 ]
Behr, TM [1 ]
机构：
[1] Univ Marburg, D-35032 Marburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2003年 / 44卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
446
引用
收藏
页码：137P / 137P
页数：1
相关论文
共 50 条
  • [1] Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-Octreotide in advanced neuroendocrine tumour patients
    Schipper, ML
    Gotthardt, M
    Béhé, M
    Arnold, R
    Behr, TM
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 292 - 292
  • [2] Our experience of therapy with high dose In111-DTPA-D-Phe octreotide in patients with neuroendocrine tumors.
    Trivizaki, E. M.
    Moshogiannis, B. G.
    Saranti, S. P.
    Iordanidou, L. A.
    Pateniotis, K. M.
    Matselas, E. S.
    Georgakopoulos, A. T.
    Koutsiouba, P. T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S326 - S326
  • [3] Treatment of patients with neuroendocrine tumors with [111In-DTPA-D-Phe]-octreotide -: The Uppsala experience
    Janson, ET
    Garske, U
    Westlin, JE
    Welin, S
    Örlefors, H
    Granberg, D
    Skogseid, B
    Eriksson, B
    Öberg, K
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 294 - 295
  • [4] Therapeutic efficacy and toxicity of 111ln-DTPA-D-Phe-Octreotide in patients with metastatic neuroendocrine gastroenteropancreatic tumors:: Preliminary results of a dose-escalation-study
    Wied, M
    Diedrich, J
    Schipper, ML
    Gotthardt, M
    Behe, M
    Höffken, HH
    Gratz, S
    Rinke, A
    Behr, TM
    Arnold, R
    GASTROENTEROLOGY, 2002, 122 (04) : A385 - A385
  • [5] A dose-escalation-study evaluating the toxicity and therapeutic efficacy of 111In-DTPA-D-Phe1-octreotide in patients with metastatic neuroendocrine tumors:: Preliminary results.
    Schipper, ML
    Gotthardt, M
    Behe, M
    Diedrich, J
    Wied, MU
    Hoeffken, H
    Gratz, S
    Schlieck, A
    Arnold, R
    Behr, TM
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 315P - 316P
  • [6] Treatment with high dose [111In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors -: Evaluation of therapeutic and toxic effects
    Janson, ET
    Eriksson, B
    Öberg, K
    Skogseid, B
    Öhrvall, U
    Nilsson, S
    Westlin, JE
    ACTA ONCOLOGICA, 1999, 38 (03) : 373 - 377
  • [7] Treatment with high dose [111In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors - evaluation of therapeutic and toxic effects
    Janson, Eva Tiensuu
    Eriksson, Barbro
    Oberg, Kjell
    Skogseid, Britt
    Ohrvall, Ulf
    Nilsson, Sten
    Westlin, Jan-Erik
    Acta Oncologica, 38 (03): : 373 - 377
  • [8] Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors
    Janson, ET
    Westlin, JE
    Öhrvall, U
    Öberg, K
    Lukinius, A
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (09) : 1514 - 1518
  • [9] Comparison of pretherapeutic dosimetry with Y-86-DOTATOC versus in-111-DTPA-octreotide in advanced neuroendocrine tumors.
    Helisch, A
    Foerster, GF
    Reber, H
    Buchholz, HG
    Arnold, R
    Goeke, B
    Weber, MM
    Wiedenmann, B
    Pauwels, S
    Bouterfa, H
    Bartenstein, P
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 151P - 151P
  • [10] Distribution and elimination characteristics of111In-DTPA-D-Phe1-octreotide and111In-DTPA-L-Phe1-octreotide in rats
    Alice Laznickova
    M. Laznicek
    F. Trejtnar
    L. Melicharova
    Kazuko Horuichi Suzuki
    Hiromichi Akizawa
    Yasushi Arano
    Akira Yokoyama
    European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27 : 37 - 43
12345